Notably, seminal work by Andy Minn’s team has demonstrated that chronic IFN-γ exposure triggers tumor immunoediting programs that promote CD8+ T cell exhaustion and drive acquired resistance to ICB therapy [59–63]. The gene discussed is CD8A; the disease is neoplasm.